After a turbulent year, Prothena is reorganizing to rally its resources around what remains in its neuroscience pipeline.
A Tufts team has published research that explains how A. baumannii builds a protective coating, allowing it to evade destruction from antibiotics.
Progress has been made in pediatric drug development, but gaps still exist. What you should know about regulatory updates from an industry expert.
Building on research into the ketogenic diet, Bloom is initially focusing on developing bacterial treatments for epilepsy.
Hard on the heels of a deal with Allergan, Aptinyx unveils plans for an $80 million IPO to accelerate work on its drugs for neurological disorders.
The deal gives Novo control of orally available LPA1 receptor antagonist EPGN696 in exchange for up to $200 million in upfront and milestone payments.
Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.
Esperion's bempedoic acid is continuing its roll, lowering LDL cholesterol in patients with atherosclerosis.
AstraZeneca has opened its new South San Francisco R&D facility, bundling five sites into a single unit at the heart of California’s biotech cluster.
The planned IPO will give Verrica the money to take a treatment for viral skin infection molluscum through phase 3 and onto the market.
The cash equips Lava to advance bispecific engagers of γδ T cells, a small subgroup of lymphocytes involved in natural and induced immunity to cancer.
